Bluebird bio's blood disorder therapy effective – FDA staff
By Mrinalika Roy June 7 (Reuters) – Bluebird bio’s blood disorder treatment demonstrates “clinically meaningful” benefit in patients, staff reviewers at the U.S. Food and Drug Administration said in briefing documents published on Tuesday. The company has applied for approval of beti-cel as a one-time gene therapy for the treatment of Beta-thalassemia patients dependent on […]
Continue Reading